The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
mTOR inhibitor everolimus (Ev) and IGFR inhibitor OSI-906 (OSI) for the treatment of patients (pts) with refractory metastatic colorectal cancer (mCRC): A Sarah Cannon Research Institute phase I trial.
L. Hart
No relevant relationships to disclose
H. A. Burris
No relevant relationships to disclose
J. R. Infante
Consultant or Advisory Role - Novartis
S. F. Jones
No relevant relationships to disclose
D. R. Spigel
Consultant or Advisory Role - Novartis (U)
J. C. Bendell
No relevant relationships to disclose